EP1322667A4 - Recepteurs du facteur de necrose tumorale 6-alpha et 6-beta - Google Patents

Recepteurs du facteur de necrose tumorale 6-alpha et 6-beta

Info

Publication number
EP1322667A4
EP1322667A4 EP01966151A EP01966151A EP1322667A4 EP 1322667 A4 EP1322667 A4 EP 1322667A4 EP 01966151 A EP01966151 A EP 01966151A EP 01966151 A EP01966151 A EP 01966151A EP 1322667 A4 EP1322667 A4 EP 1322667A4
Authority
EP
European Patent Office
Prior art keywords
beta
alpha
necrosis factor
tumor necrosis
factor receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01966151A
Other languages
German (de)
English (en)
Other versions
EP1322667A2 (fr
Inventor
Reiner L Gentz
Reinhard Ebner
Guo-Liang Yu
Steven M Ruben
Jian Ni
Ping Feng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1322667A2 publication Critical patent/EP1322667A2/fr
Publication of EP1322667A4 publication Critical patent/EP1322667A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP01966151A 2000-08-25 2001-08-24 Recepteurs du facteur de necrose tumorale 6-alpha et 6-beta Withdrawn EP1322667A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US22759800P 2000-08-25 2000-08-25
US227598P 2000-08-25
US25213100P 2000-11-21 2000-11-21
US252131P 2000-11-21
US30322401P 2001-07-06 2001-07-06
US303224P 2001-07-06
PCT/US2001/026396 WO2002018622A2 (fr) 2000-08-25 2001-08-24 Recepteurs du facteur de necrose tumorale 6$g(a) et 6$g(b)

Publications (2)

Publication Number Publication Date
EP1322667A2 EP1322667A2 (fr) 2003-07-02
EP1322667A4 true EP1322667A4 (fr) 2004-08-18

Family

ID=27397742

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01966151A Withdrawn EP1322667A4 (fr) 2000-08-25 2001-08-24 Recepteurs du facteur de necrose tumorale 6-alpha et 6-beta

Country Status (4)

Country Link
EP (1) EP1322667A4 (fr)
AU (1) AU2001286688A1 (fr)
CA (1) CA2420593A1 (fr)
WO (1) WO2002018622A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018213315A1 (en) * 2017-01-26 2019-07-25 Oklahoma Medical Research Foundation Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399666A1 (fr) * 1989-04-29 1990-11-28 Delta Biotechnology Limited Protéines de fusion contenant des fragments N-terminaux de l'albumine de sérum humaine
WO1993015199A1 (fr) * 1992-01-31 1993-08-05 Rhone-Poulenc Rorer S.A. Nouveaux polypeptides biologiquement actifs, leur preparation et composition pharmaceutique les contenant
WO1997024445A1 (fr) * 1995-12-30 1997-07-10 Delta Biotechnology Limited Proteines de fusion recombinees d'hormone de croissance et d'albumine serique
WO1998030694A2 (fr) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. RECEPTEURS 6α ET 6β DU FACTEUR DE NECROSE TUMORALE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885800A (en) * 1997-02-04 1999-03-23 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor, TR4
DK1015587T3 (da) * 1997-09-18 2008-08-25 Genentech Inc DcR3 polypeptid, en TNFR-homolog
HUP0102067A2 (hu) * 1998-03-30 2001-10-28 Eli Lilly And Co. A TNF receptorcsaládba tartozó érett FLINT (mFLINT) polipeptid vagy más néven az OPG3 terápiás alkalmazásai

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399666A1 (fr) * 1989-04-29 1990-11-28 Delta Biotechnology Limited Protéines de fusion contenant des fragments N-terminaux de l'albumine de sérum humaine
WO1993015199A1 (fr) * 1992-01-31 1993-08-05 Rhone-Poulenc Rorer S.A. Nouveaux polypeptides biologiquement actifs, leur preparation et composition pharmaceutique les contenant
WO1997024445A1 (fr) * 1995-12-30 1997-07-10 Delta Biotechnology Limited Proteines de fusion recombinees d'hormone de croissance et d'albumine serique
WO1998030694A2 (fr) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. RECEPTEURS 6α ET 6β DU FACTEUR DE NECROSE TUMORALE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SYED S ET AL: "Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 89, no. 9, 1 May 1997 (1997-05-01), pages 3243 - 3252, XP002130705, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
EP1322667A2 (fr) 2003-07-02
WO2002018622A2 (fr) 2002-03-07
WO2002018622A3 (fr) 2002-08-29
CA2420593A1 (fr) 2002-03-07
AU2001286688A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
AU5945801A (en) Opoid antagonist compositions and dosage forms
MXPA03006121A (es) Terapia de combinacion usando inhibidores del receptor tirosin-cinasa e inhibidores de la angiogenesis.
HK1053124A1 (en) Substituted quinazoline derivatives and their use as inhibitors
IL150632A0 (en) Corticotropin releasing factor antagonists
IL154131A0 (en) Quinazoline derivatives
HUP0401461A3 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
HK1082690A1 (en) Tumor necrosis factor antagonists and their use in endometriosis
AU7616001A (en) Probiotic recolonisation therapy
AU2002359126A8 (en) Benzodiazepine derivatives, preparation thereof and use thereof
AU2002359123A8 (en) Benzodiazepine derivatives, preparation thereof and use thereof
EG22612A (en) Pyrimidine compounds and their use
TWI318974B (en) Acylaminothiazole derivatives, their preparation and their therapeutic use
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
ZA200307306B (en) Indolines, substituted in portion 6, and their use as kinase inhibitors.
EP1294949A4 (fr) Facteur de necrose tumorale humain delta et epsilon
GB0002835D0 (en) Drug resistance in cancer
EP1322667A4 (fr) Recepteurs du facteur de necrose tumorale 6-alpha et 6-beta
GB0007530D0 (en) Trityl-type compounds and their use
GB0021497D0 (en) Compounds and their use
HUP0401162A3 (en) Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives
GB0018887D0 (en) Compound and their therapeutic use
HK1065792A1 (en) 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino Ä4,5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
GB0200843D0 (en) Benzodioxinopyrroles their preparation and use
AU7660601A (en) Pseudo-metalloproteins, their preparation and use
AU6884801A (en) Therapeutic compounds and methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030312

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040702

17Q First examination report despatched

Effective date: 20050525

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051005